Transplantation outcome
| . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | ||
|---|---|---|---|---|---|
| Stage at time of HSCT, no. (%) | — | CP, 4 (21) | Advanced phase,* 15 (79) | CP, 12 (43) | Advanced phase,* 16 (57) |
| Best response, no. (%) | |||||
| CMR | 31 (66) | 4 (100) | 7 (47) | 10 (83) | 10 (62) |
| MMR | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (6) |
| CCyR | 11 (23) | 0 (0) | 5 (33) | 1 (8) | 5 (31) |
| Relapse, no. (%) | 18 (38) | 1 (25) | 7 (47) | 3 (25) | 7 (44) |
| Total deaths, no. (%) | 16 (34) | 2 (50) | 8 (53) | 2 (17) | 4 (25) |
| Deaths in CR, no. (%) | 7 (15) | 2 (50) | 3 (20) | 1 (8) | 1 (6) |
| Alive in CR, no. (%) | 22 (47) | 1 (25) | 5 (33) | 8 (67) | 8 (50) |
| . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | ||
|---|---|---|---|---|---|
| Stage at time of HSCT, no. (%) | — | CP, 4 (21) | Advanced phase,* 15 (79) | CP, 12 (43) | Advanced phase,* 16 (57) |
| Best response, no. (%) | |||||
| CMR | 31 (66) | 4 (100) | 7 (47) | 10 (83) | 10 (62) |
| MMR | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (6) |
| CCyR | 11 (23) | 0 (0) | 5 (33) | 1 (8) | 5 (31) |
| Relapse, no. (%) | 18 (38) | 1 (25) | 7 (47) | 3 (25) | 7 (44) |
| Total deaths, no. (%) | 16 (34) | 2 (50) | 8 (53) | 2 (17) | 4 (25) |
| Deaths in CR, no. (%) | 7 (15) | 2 (50) | 3 (20) | 1 (8) | 1 (6) |
| Alive in CR, no. (%) | 22 (47) | 1 (25) | 5 (33) | 8 (67) | 8 (50) |
— indicates not applicable; CMR, complete molecular response; MMR, major molecular response; and CR, complete remission.
Advanced phase: AP, BP, and second CP.